Mylo launches in Hong Kong with fresh food and microbiome focus

Mylo, a Hong Kong pet nutrition startup developed with a board-certified veterinary nutritionist, has formally rolled out its commercial platform after launching in June 2026. The company is pitching itself as Hong Kong’s first and only BCVN-formulated pet nutrition brand, combining fresh meals, micronutrient mixes for home-cooked feeding, and microbiome-focused supplements under one longevity-oriented umbrella. (en.prnasia.com)

The launch lands at a moment when fresh feeding and functional supplementation continue to gain traction with pet parents, while veterinarians are fielding more questions about formulation quality, evidence standards, and the role of probiotics in everyday care. Mylo’s own positioning mirrors that shift: its website explicitly frames the brand around questions commonly associated with veterinary nutrition due diligence, including who formulates the food, whether diets meet recognized nutrient standards, how quality is controlled, and whether the company supports nutrition research. (mylo-pets.com)

In its September 24, 2026 announcement, Mylo said it has raised more than HK$6 million in initial funding and built a three-part product system: MyloMeals fresh diets, MyloMix nutrient blends for guided home-prepared feeding, and MyloBiome functional probiotic formulas. The company also said a 16-week collaborative microbiome study with Hong Kong Polytechnic University and Hong Kong Homeless Dog Shelter found MyloBiome inhibited 95% of harmful bacteria. The release did not provide a linked manuscript or detailed methods in the material reviewed, so that claim currently rests on company-issued communications and product pages rather than a publicly available peer-reviewed paper. (en.prnasia.com)

Mylo’s nutrition credentials are central to its message. The company names Dr. Moran Tal-Gavriel as chief veterinary nutrition officer and says she leads formula development. Independent background sources confirm Tal-Gavriel is listed by the European Board of Veterinary Specialisation as a specialist in veterinary and comparative nutrition, and other industry sources describe her as a board-certified veterinary nutritionist with experience spanning clinical practice, research, public health, and pet food. (en.prnasia.com)

The company is also trying to build credibility through outside affiliations. Mylo says it is collaborating with local university teams on microbiome work and has launched what it describes as Asia’s largest canine fecal microbiota database and longevity research program. It has also brought on Sylvia Burbery, formerly a senior Royal Canin executive in Asia Pacific and emerging markets, as a board advisor, according to company and executive LinkedIn posts. That combination of specialist formulation, research branding, and industry leadership experience suggests Mylo is aiming to be more than a direct-to-consumer fresh food company. (en.prnasia.com)

Expert reaction outside the company was limited in the material available, but Mylo’s own published comments emphasize prevention and microbiome support. On the brand’s site, Tal-Gavriel describes MyloBiome as a targeted probiotic designed with clinically proven strains and above-industry doses, while chief scientific officer Prof. William Tai says the company’s strains are designed to survive gastric acid and reach the gut alive. Those are company statements, not independent validation, but they show where Mylo expects to differentiate in a crowded supplement market. (mylo-pets.com)

Why it matters: For veterinary professionals, Mylo’s launch is a useful case study in where premium companion animal nutrition is heading in Asia: fresh-food formats, microbiome claims, and specialist-led formulation are becoming commercial differentiators. That may help raise the bar for transparency and nutrition expertise, especially in markets where pet parents are increasingly skeptical of generic formulations. At the same time, it puts more pressure on clinicians to separate credential-based reassurance from evidence-based outcomes. Claims about bacterial inhibition, healthy aging, oral health, or reduced need for anesthetic dental cleanings may attract attention, but they’ll matter most if backed by published data, clear endpoints, and reproducible results. (mylo-pets.com)

What to watch: The next key milestones are likely to be publication or conference presentation of the microbiome study, more detail on the stool-bank and longevity protocol, and signs that Mylo’s clinic collaborations or research footprint are expanding beyond an initial Hong Kong base. If those pieces materialize, Mylo could become an early regional example of a nutrition brand trying to bridge consumer wellness, veterinary credibility, and translational microbiome research. (en.prnasia.com)